Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 95,028,104
  • Shares Outstanding, K 1,319,660
  • Annual Sales, $ 32,639 M
  • Annual Income, $ 18,108 M
  • 36-Month Beta 1.20
  • Price/Sales 3.01
  • Price/Book 5.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.23 +0.94%
on 01/19/17
76.98 -6.60%
on 01/04/17
-2.15 (-2.90%)
since 12/20/16
3-Month
70.83 +1.51%
on 12/08/16
80.00 -10.12%
on 11/10/16
-2.41 (-3.24%)
since 10/20/16
52-Week
70.83 +1.51%
on 12/08/16
103.10 -30.26%
on 04/26/16
-18.65 (-20.60%)
since 01/20/16

Most Recent Stories

More News
Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works

Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works

2017 Community Awards Honor Academic and Industry Leaders, Georgia Power, UGA Research Center

Georgia Bio each year recognizes individuals, companies and organizations for significant contributions to Georgia's life sciences industry with its Georgia Bio Community Awards. The recipients...

4 Top Biotech Mutual Funds for 2017

Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance

Stock Market News for January 12, 2017

Benchmarks ended a volatile trading session in the green on Wednesday following President-elect Donald Trump's first news conference in months

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Is the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock?

Investors in Gilead Sciences Inc. (GILD) need to pay close attention to the stock based on moves in the options market lately.

Gilead (GILD) HBV Drug Vemlidy Receives European Approval

Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.

Trump Attacks Biotech & Pharma: ETFs Bleed

Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.

Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment

After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.

MOLOGEN AG: Grant to collaboration partner for combination study in HIV with lead product lefitolimod

--Funding for a novel "kick-and-kill" concept of HIV eradication

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 72.70
1st Resistance Point 72.14
Last Price 71.90
1st Support Level 71.12
2nd Support Level 70.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.